ライフサイエンスコーパス: phosphodiesterase

1 rate cAMP (adenylyl cyclase) and degrade it (phosphodiesterase).

2 by increased activity of a c-di-GMP specific phosphodiesterase.

3 ion increases resistance against snake venom phosphodiesterase.

4 e phosphorylation profile of a putative cGMP-phosphodiesterase.

5 lysis is increased by activation of the PDE5 phosphodiesterase.

6 o evolutionarily distinct phosphatases and a phosphodiesterase.

7 zed solely among DHH-DHHA1 domain-containing phosphodiesterases.

8 e report that ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is preferentially upregulate

9 g mutation in ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) was identified in all patien

10 in (ANK), and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1).

11 te inhibitory activities against tyrosyl-DNA phosphodiesterase 1 (TDP1) and tyrosyl-DNA phosphodieste

12 ted to the reduced expression of tyrosyl-DNA-phosphodiesterase 1 (TDP1), a DNA repair enzyme, in ATL

13 plementing protein 1 (XRCC1) and tyrosyl-DNA phosphodiesterase 1 (TDP1), using fluorescence- and ligh

14 hosphatases (ecto-nucleotide pyrophosphatase/phosphodiesterases 1 and 3).

15 CD39, CD73, ecto-nucleotide pyrophosphatase/phosphodiesterases 1 and 3, CD157, CD38) for the acceler

16 The cyclic nucleotide phosphodiesterase 10A (PDE10) has been mostly studied as

17 nes as a novel class of potent and selective phosphodiesterase 10A (PDE10A) inhibitors.

18 Phosphodiesterase 10A (PDE10A) is a basal ganglia expres

19 Phosphodiesterase 10A (PDE10A) is a dual substrate PDE t

20 Phosphodiesterase 10A (PDE10A) is a novel therapeutic ta

21 Phosphodiesterase 10A (PDE10A) is an enzyme present in s

22 Phosphodiesterase 10A (PDE10A) is enriched in the striat

23 Four novel phosphodiesterase 10A (PDE10A) PET tracers have been syn

24 l medium spiny neurons, which highly express phosphodiesterase 10A (PDE10A).

25 We report that changes of phosphodiesterase-10A (PDE10A) can map widespread functi

26 isorder has been genetically associated with Phosphodiesterase 11A (PDE11A), and lithium decreases PD

27 Phosphodiesterase 12 (PDE12) was the first cellular 2-5A

28 Pharmacological inhibition of phosphodiesterase 2 (BAY 60-7550, BAY) led to a signific

29 METHODS AND Pharmacological inhibition of phosphodiesterase 2 (BAY 60-7550, BAY) led to a signific

30 Phosphodiesterase 2 (PDE2) inhibitors increase the intra

31 In this study, we examined the role of phosphodiesterase 2 (PDE2), a medium spiny neuron-enrich

32 litates a proteasome-independent tyrosyl-DNA phosphodiesterase 2 (TDP2) hydrolase activity on stalled

33 Tyrosyl DNA phosphodiesterase 2 (TDP2) is a multifunctional protein

34 Mammalian Tyrosyl-DNA phosphodiesterase 2 (Tdp2) reverses Topoisomerase 2 (Top

35 A phosphodiesterase 1 (TDP1) and tyrosyl-DNA phosphodiesterase 2 (TDP2), two enzymes that are involve

36 d breaks are rejoined in part by tyrosyl-DNA phosphodiesterase 2 (TDP2)-dependent non-homologous end-

37 Greater phosphodiesterase 2 abundance protects against arrhythmi

38 Endogenous phosphodiesterase 2 contributes to heart rate regulation

39 To explore the role of phosphodiesterase 2 in cardiac function, propensity to a

40 Phosphodiesterase 2 is a dual substrate esterase, which

41 RATIONALE: Phosphodiesterase 2 is a dual substrate esterase, which

42 Myocardial phosphodiesterase 2 is upregulated in human heart failur

43 Activating myocardial phosphodiesterase 2 may, thus, represent a novel intrace

44 Conversely, ECG telemetry in heart-specific phosphodiesterase 2-transgenic (TG) mice showed a marked

45 by spatial redistribution of cGMP-sensitive phosphodiesterases 2 and 3 between both receptor compart

46 We previously showed that 2',5'-phosphodiesterases (2',5'-PDEs) encoded by the prototypi

47 titis virus (MHV) and MERS-CoV, encode 2',5'-phosphodiesterases (2',5'-PDEs) that antagonize the OAS-

48 Phosphodiesterase 2A (PDE2A) inhibitors have been report

49 pression of cGKI and enhance cGMP-stimulated phosphodiesterase 2A (PDE2A) levels.

50 The enzyme phosphodiesterase 2A (PF-05270430) is a potential target

51 This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand (18)F-PF-0527043

52 st likely by the activation of sphingomyelin phosphodiesterase 3 (SMPD3) and cytoskeletal remodelling

53 Sphingomyelin phosphodiesterase 3 (SMPD3), a lipid-metabolizing enzyme

54 ar calcium was found to induce sphingomyelin phosphodiesterase 3 expression and the secretion of calc

55 Clinical experience with phosphodiesterase 3 inhibitors (PDE3i) in pediatric pati

56 ro, and chemical inhibition of sphingomyelin phosphodiesterase 3 prevented VSMC calcification.

57 their release was regulated by sphingomyelin phosphodiesterase 3.

58 Quinidine (10 muM) and the phosphodiesterase-3 inhibitors cilostazol (10 muM) and m

59 Cyclic nucleotide phosphodiesterase 3A (PDE3) regulates cAMP-mediated sign

60 rt six missense mutations in PDE3A (encoding phosphodiesterase 3A) in six unrelated families with men

61 y targeted inactivation of cyclic nucleotide phosphodiesterase 3b (Pde3b) gene, which encodes PDE3B,

62 tein kinase G (PKG), protein kinase A (PKA), phosphodiesterase 3B (PDE3B), and a membrane-permeable c

63 ipolytic action of insulin is believed to be phosphodiesterase 3B (PDE3B), whose phosphorylation by A

64 The enzyme acid sphingomyelinase-like phosphodiesterase 3B (SMPDL3B) was shown to act as a neg

65 Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage o

66 The phosphodiesterase 4 (PDE4) family coordinates the degrad

67 Members of the cAMP-specific phosphodiesterase 4 (PDE4) family, which contains >25 di

68 Inhibition of cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4) has been proposed as a potent

69 Phosphodiesterase 4 (PDE4) has four isoforms (PDE4A-D) w

70 Phosphodiesterase 4 (PDE4) inhibition restores the suppr

71 loped to enhance the targeting efficiency of phosphodiesterase 4 (PDE4) inhibitor to the lungs for tr

72 Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available i

73 Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing en

74 Phosphodiesterase 4 (PDE4) is an essential contributor t

75 scaffolding protein DISC1 and cAMP-degrading phosphodiesterase 4 (PDE4) to regulate PDE4 activity.

76 ed to a dual inhibition of p38alpha MAPK and phosphodiesterase 4 (PDE4), and the potential benefits a

77 P elevations in the PFC secondary to reduced phosphodiesterase 4 activity present in Disc1 deficiency

78 Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide

79 ls, including macrolides, CXCR2 antagonists, phosphodiesterase 4 inhibitors, p38 mitogen-activating p

80 vators of adenylate cyclase or inhibitors of phosphodiesterase 4) promoted degradation of short-lived

81 atory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pe

82 t on NMDAR expression and function through a phosphodiesterase 4/PKA/CREB-dependent mechanism, which

83 We found that the phosphorylation of phosphodiesterase-4 (PDE4) by cyclin-dependent protein k

84 ctivity by using (11)C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients a

85 ctivity by using (11)C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients a

86 Here we investigated whether 3 phosphodiesterase-4 (PDE4) inhibitors (rolipram, roflumi

87 UD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inh

88 ions or treatment with the anti-inflammatory phosphodiesterase-4 inhibitor roflumilast prevents COPD-

89 Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inf

90 cofilin activity is caused by cAMP-degrading phosphodiesterase-4A5 (PDE4A5), which hampers cAMP-PKA-L

91 In this study, we report that a selective phosphodiesterase 4B (PDE4B) inhibitor reduces chronic c

92 991 increases the Vmax of cyclic nucleotide phosphodiesterase 4B (PDE4B) without affecting intracell

93 Phosphodiesterase-4B (PDE4B) is an important phosphodies

94 TBI also acutely upregulates phosphodiesterase 4B2 (PDE4B2), which terminates cAMP si

95 Here we show that phosphodiesterase 4D (PDE4D) acts downstream of Neuropil

96 ive regulation of cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) and the regulatory subunit

97 t, one genomewide significant hit located in phosphodiesterase 4D, cAMP-specif (PDE4D) and 26 SNPs wi

98 therefore explored if BPN14770, a prototypic phosphodiesterase-4D negative allosteric modulator (PDE4

99 or activators, adenylate cyclase activators, phosphodiesterase 4D3 inhibitors, T-oligos, and micropht

100 Phosphodiesterase 5 (PDE5) hydrolyzes cyclic guanosine m

101 dystrophin, restoration of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improv

102 Phosphodiesterase 5 (PDE5) inhibitors limit myocardial i

103 ric oxide donor sodium nitroprusside and the phosphodiesterase 5 inhibitor sildenafil compared with h

104 Sildenafil, an FDA-approved phosphodiesterase 5 inhibitor that enhances NO signaling

105 We tested whether tadalafil, a phosphodiesterase 5 inhibitor used to treat erectile dys

106 Endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitors (PDE5I) are long-term the

107 We speculate that beneficial effects of phosphodiesterase 5 inhibitors in the systemic vasculatu

108 Early studies showed beneficial effects of phosphodiesterase 5 inhibitors on cardiovascular functio

109 mation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exerc

110 Here we report that phosphodiesterase-5 (PDE5) gene expression and PDE activ

111 oth muscle cells (PASMCs), and inhibition of phosphodiesterase-5 (PDE5) has been shown to suppress TR

112 S-LTP identified vardenafil and Bay-73-6691 (phosphodiesterase-5 and -9 inhibitors, respectively) as

113 ism, angiogenesis, adrenergic signaling, and phosphodiesterase-5 expression.

114 preserved ejection fraction enrolled in the PhosphodiesteRasE-5 Inhibition to Improve CLinical Statu

115 h preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Statu

116 Phosphodiesterase-5 inhibition with sildenafil compared

117 Treatment of mice with the phosphodiesterase-5 inhibitor vardenafil (Levitra) mobil

118 The phosphodiesterase-5 inhibitor, sildenafil, potentiates N

119 ered by cinaciguat, riociguat, and different phosphodiesterase-5 inhibitors and beneficial actions of

120 Phosphodiesterase-5 inhibitors prevent the breakdown of

121 rate that the increase of cGMP levels by the phosphodiesterase-5 inhibitors sildenafil and vardenafil

122 ailable-ie, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclas

123 MP/PKG2 signaling, and can be targeted using phosphodiesterase-5 inhibitors.

124 ivation and inhibition of the cGMP-degrading phosphodiesterase-5, ischemic preconditioning, and postc

125 A2 (PLA2) and ectonucleotide pyrophophatase/phosphodiesterase 6 (ENPP6)-act in sequence upon phospha

126 reduced along with a robust decrease in rod phosphodiesterase 6 (PDE6) and G-protein receptor kinase

127 Phosphodiesterase 6 (PDE6) is the effector enzyme in the

128 important biological role as a chaperone of phosphodiesterase 6 (PDE6), an effector enzyme of the vi

129 ciation of isoprenylated transducin and cone phosphodiesterase 6 (PDE6alpha') with photoreceptor memb

130 ARL3 is an effector of phosphodiesterase 6 Delta (PDE6D), a prenyl-binding prot

131 The phosphodiesterase 6 delta subunit (PDE6delta) shuttles s

132 Phosphodiesterase-6 (PDE6) is a multisubunit enzyme that

133 hesized that RP associated with mutations in phosphodiesterase-6 (PDE6) provokes a metabolic aberrati

134 Furthermore, assembled phosphodiesterase-6 (PDE6) subunits, rod transducin and

135 osine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis

136 iliary proteins: PDE6delta (delta subunit of phosphodiesterase; a prenyl-binding protein) and INPP5E

137 The lipid-modulating enzyme sphingomyelin phosphodiesterase acid-like 3B (SMPDL3b) is a key determ

138 Sphingomyelin phosphodiesterase, acid-like 3A (SMPDL3A) is a member of

139 used the models to test the hypothesis that phosphodiesterases act as functional barriers to diffusi

140 ivates CFTR in Xenopus oocytes by inhibiting phosphodiesterase activity and subsequent stimulation of

141 to the myofilaments together with a reduced phosphodiesterase activity associated with the myofibril

142 ortholog, we show that yeast Usb1 has cyclic phosphodiesterase activity that leaves a terminal 3' pho

143 erminal catalytic domain responsible for its phosphodiesterase activity, and a functionally uncharact

144 tenuated in liver replication due to loss of phosphodiesterase activity, by which the wild-type virus

145 tenuated in liver replication due to loss of phosphodiesterase activity, which the wild-type (WT) vir

146 ay be related to a differential switching in phosphodiesterase activity.

147 that CodY consists of a GAF (cGMP-stimulated phosphodiesterases, adenylate cyclases, FhlA) domain tha

148 MP-specific and -regulated cyclic nucleotide phosphodiesterase, adenylyl cyclase, and E. coli transcr

149 romobilin chromophore buried within the cGMP phosphodiesterase/adenylyl cyclase/FhlA (GAF) domain, an

150 dels predict that under realistic conditions phosphodiesterases alone were insufficient to generate s

151 attributed to a progressive depletion of the phosphodiesterase along the rod OS.

152 Trl1 is composed of C-terminal cyclic phosphodiesterase and central polynucleotide kinase doma

153 l defined electron density for p261C and the phosphodiesterase and oligonucleotide/oligosaccharide-bi

154 vidence that the GP12 protein possesses both phosphodiesterase and phosphomonoesterase activities.

155 ted a crucial functional interaction between phosphodiesterases and ABCC4.

156 Redistribution of cGMP-regulated phosphodiesterases and functional reorganization of rece

157 iated mainly by two glycerophosphoryldiester phosphodiesterases and three patatin-like phospholipases

158 Phosphodiesterases are proving to be fruitful targets fo

159 t starvation triggers c-di-GMP hydrolysis by phosphodiesterase BifA, releasing inhibition of protease

160 sphate (cAMP) signaling by increasing type 4 phosphodiesterase catabolism of cAMP when cAMP concentra

161 he myelin protein 2'-3'-cyclic nucleotide 3'-phosphodiesterase (CNP) are associated with the schizoph

162 letion, and renal 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) metabolizes 2',3'-cAMP to 2'-

163 Phosphodiesterase-delta (PDEdelta) binds to KRAS4b and p

164 and flagellum-driven motility, GcbA and the phosphodiesterase DipA act within different signaling ne

165 sa proteins, including BdlA and the c-di-GMP phosphodiesterases DipA, RbdA, and NbdA, have been shown

166 main and for the linker connecting it to the phosphodiesterase domain.

167 e studied the EAL signature motif-containing phosphodiesterase domains from the Pseudomonas aeruginos

168 n of the GPR158 C terminus contained several phosphodiesterase E gamma-like motifs and selectively re

169 in remyelination, 2',3'-cyclic-nucleotide 3'-phosphodiesterase-EGFP(+) mice were treated with cuprizo

170 rther by showing that the S. aureus c-di-AMP phosphodiesterase enzyme GdpP is inhibited in a dose-dep

171 L. monocytogenes mutant that lacks c-di-AMP phosphodiesterases exhibited elevated c-di-AMP levels, h

172 of chronic hypoxia prevented the increase in phosphodiesterase expression (72.5 +/- 22.4%), protected

173 , particularly PknA in trans-phosphorylating phosphodiesterase from Mycobacterium tuberculosis (mPDE)

174 Glycerophosphodiester phosphodiesterases (GDPDs; EC 3.1.4.46) typically hydrol

175 which harbor a mutation in the rod-specific phosphodiesterase gene Pde6beta and lose rod and cone ph

176 does so in a manner that depends on the gdpP phosphodiesterase gene.

177 All restriction enzymes examined are phosphodiesterases generating 3-OH and 5-P ends, but one

178 Although the two cAMP phosphodiesterase genes PDE1 and PDE2 had overlapping fu

179 [p.Phe334Leu] in one individual), encoding a phosphodiesterase highly and selectively present in MSNs

180 ne the steps necessary to purify snake venom phosphodiesterase I (SVP) and describe two alternatives

181 Tyrosyl-DNA phosphodiesterase I (Tdp1) catalyzes the repair of 3'-DN

182 ds in the presence or absence of tyrosyl DNA phosphodiesterase I (TDP1); a key TOP1-mediated protein-

183 Tyrosyl DNA phosphodiesterase II (TDP2) is a recently discovered enz

184 his study, we assessed whether cilostazol, a phosphodiesterase III inhibitor, could protect against t

185 Phosphodiesterase-4B (PDE4B) is an important phosphodiesterase in the hippocampal formation, is a maj

186 nship between ABCC4 transporter function and phosphodiesterases in accounting for the cAMP-directed a

187 ets that ABCC4 inhibition, when coupled with phosphodiesterase inhibition, strongly impaired platelet

188 muscle cells in the presence and absence of phosphodiesterase inhibition.

189 or environmental acidification, while a cGMP-phosphodiesterase inhibitor circumvents egress repressio

190 f cAMP, or a blockade of cAMP degradation by phosphodiesterase inhibitor decreased NLRP3 activation.

191 e attenuation of platelet aggregation by the phosphodiesterase inhibitor EHNA (a non-ABCC4 substrate)

192 dichotomy was recapitulated by zaprinast, a phosphodiesterase inhibitor that elevated cGMP and separ

193 gondii In doing so, we took advantage of the phosphodiesterase inhibitor zaprinast, which we show act

194 Ibudilast, a nonselective phosphodiesterase inhibitor, is used clinically in Asia

195 pretreatment with rolipram, a selective cAMP phosphodiesterase inhibitor.

196 rovide new insights into mechanisms by which phosphodiesterase inhibitors may block malaria parasite

197 y 36,000 compounds, we identified a class of phosphodiesterase inhibitors that suppress let-7 targets

198 s confirmed by adenylate cyclase activators, phosphodiesterase inhibitors, and most notably by stimul

199 ished by deltarasin, an inhibitor of the Ras-phosphodiesterase interaction, or by simultaneous deplet

200 ural homology search has shown similarity to phosphodiesterases involved in cleavage of cyclic nucleo

201 gative feedback regulation of cAMP levels by phosphodiesterase is well-established in eukaryotic cell

202 easurements of various enzymatic activities (phosphodiesterase, kinase, bacterial translation) under

203 in hydrolyzing cellular cAMP, we utilized a phosphodiesterase knock-out Escherichia coli strain, Del

204 P-dependent protein kinase (PKA), and type 4 phosphodiesterase may be involved in attenuating the cAM

205 cyclic diguanosine monophosphate (c-di-GMP) phosphodiesterase MbaA.

206 Our results show that a DeltabpdA phosphodiesterase mutant producing excess c-di-GMP displ

207 sis, including Gde1, a glycerophosphodiester phosphodiesterase not previously implicated in triglycer

208 se belongs to the nucleotide pyrophosphatase/phosphodiesterase (NPP) family, the members of which hyd

209 Xanthomonas citri nucleotide pyrophosphatase/phosphodiesterase (NPP)] and distinct differences from t

210 The cGMP phosphodiesterase of rod photoreceptor cells, PDE6, is t

211 ctors, including expression of any number of phosphodiesterases (of which there are 24 genes plus spi

212 eviously characterised two-metal binding EAL-phosphodiesterases, PA3825(EAL) in complex with pGpG pro

213 Phosphodiesterase (PDE) 10A is an enzyme involved in the

214 cells, we show that combining inhibitors of phosphodiesterase (PDE) 3 and PDE4 provides greater bene

215 As part of our effort in identifying phosphodiesterase (PDE) 4B-preferring inhibitors for the

216 Inhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster stat

217 Using the FRET approach and in vitro phosphodiesterase (PDE) activity assays, we show that at

218 eurons, suggesting differential switching in phosphodiesterase (PDE) activity.

219 systematic analysis is presented of the 220 phosphodiesterase (PDE) catalytic domain crystal structu

220 The structured portion of p70 includes a phosphodiesterase (PDE) domain and an oligonucleotide/ol

221 regulator domain, and a C-terminal c-di-GMP phosphodiesterase (PDE) domain.

222 His-associated (DHH/DHHA1) domain-containing phosphodiesterase (PDE) GdpP, S. aureus produces a secon

223 ntification of novel 3',5'-cyclic nucleotide phosphodiesterase (PDE) inhibitors, concentrating on bot

224 equired for social memory formation, but the phosphodiesterase (PDE) involved remains unknown.

225 Interestingly, the expression of multiple phosphodiesterase (PDE) isoforms, including PDE2A, PDE3A

226 V]) nonstructural protein 2 (ns2) is a 2',5'-phosphodiesterase (PDE) that cleaves 2-5A, thereby antag

227 -adenylyl cyclase that produces c-di-AMP and phosphodiesterase (PDE) that degrades c-di-AMP.

228 le expressed on Th2 lymphocytes (CRTh2), and phosphodiesterase (PDE)-4 inhibitors.

229 Here, we show that the dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)

230 regulators of intracellular cAMP gradients, phosphodiesterases (PDE) mediate fundamental aspects of

231 Phosphodiesterases (PDE-As) end signaling by linearizing

232 olecular level, we find that miR-378 targets phosphodiesterase Pde1b in BAT but not in WAT.

233 induced by concurrent inhibition of the cAMP phosphodiesterases PDE4 and PDE8.

234 Inhibition of type 4 phosphodiesterase (PDE4) and elevation of cyclic adenosi

235 By blocking cAMP degradation, type 4 cAMP phosphodiesterase (PDE4) inhibitors activate cAMP-mediat

236 Type 4 phosphodiesterases (PDE4) are key cAMP-hydrolyzing enzym

237 rictly controlled by the opposing actions of phosphodiesterase (PDE6) and retinal guanylyl cyclases (

238 le assembly of the retinal cyclic GMP (cGMP) phosphodiesterase (PDE6) holoenzyme.

239 We examined the role of cGMP phosphodiesterase (PDE6) in this difference by expressin

240 and to determine the catalytic domain of the phosphodiesterase PdeA.

241 cAMP phosphodiesterases PDEB1 and PDEB2 were found to be esse

242 es (activation phase) and cAMP hydrolysis by phosphodiesterases (PDEs) (termination phase).

243 ween control and DCM iPSC-CMs, we found that phosphodiesterases (PDEs) 2A and PDE3A were upregulated

244 Phosphodiesterases (PDEs) are enzymes responsible for ca

245 the biofilm lifestyle, c-di-GMP hydrolysing phosphodiesterases (PDEs) have been identified as key ta

246 ic functions for different cyclic nucleotide phosphodiesterases (PDEs) have not yet been identified i

247 The cAMP-degrading enzymes phosphodiesterases (PDEs) play a key role in shaping loc

248 also suggests that cyclic nucleotide coupled phosphodiesterases (PDEs) play a key role limiting the h

249 -dependent kinases, making cyclic nucleotide phosphodiesterases (PDEs) potential regulators of synapt

250 f trypanosomatid adenylyl cyclases (ACs) and phosphodiesterases (PDEs) since their discoveries 40 yea

251 ted to encode diguanylate cyclases (DGCs) or phosphodiesterases (PDEs) were screened for their involv

252 rotein-coupled receptors, adenylyl cyclases, phosphodiesterases (PDEs)), and receptor tyrosine kinase

253 The cAMP-degrading enzymes, phosphodiesterases (PDEs), localise to specific subcellu

254 contains a rich variety of cyclic nucleotide phosphodiesterases (PDEs), which play a critical role in

255 s, cyclic nucleotide levels are regulated by phosphodiesterases (PDEs), with PDE4s predominantly resp

256 esis by adenylyl cyclases and degradation by phosphodiesterases (PDEs).

257 cAMP can be hydrolyzed by various phosphodiesterases (PDEs).

258 on, which are regulated by cyclic nucleotide phosphodiesterases (PDEs).

259 ion adopted in the catalytic site of the EAL phosphodiesterases (PDEs).

260 whereas it is degraded by c-di-GMP-specific phosphodiesterases (PDEs).

261 any of the individual c-di-GMP synthases or phosphodiesterases (PDEs).

262 stent with reported effects of inhibition of phosphodiesterases (PDEs).

263 er control of the 2',3'-cyclic nucleotide 3'-phosphodiesterase promoter, exhibited thicker PNS and CN

264 e adenylate cyclases ACG or ACR, or the cAMP phosphodiesterase RegA.

265 n by inhibiting P2Y12 receptors and platelet phosphodiesterase, respectively, but share the capacity

266 Enhanced stability against snake venom phosphodiesterase resulted from modification of the 3'-e

267 ed using a recombinant glycerophosphodiester phosphodiesterase (rGlpQ) protein.

268 ) itself, the NO -activated form of sGC, and phosphodiesterase(s) (PDE).

269 ingomyelin synthases (SMS) and sphingomyelin phosphodiesterase (SMase) enzymes may play roles in SM d

270 We illustrate how systematic mining of this phosphodiesterase structure and ligand interaction annot

271 dducts and their known repair by tyrosyl-DNA-phosphodiesterase (TDP) 1 or TDP2 suggested that HBV may

272 hatidylserine synthase (PSS) and tyrosyl-DNA phosphodiesterase (TDP), and conserved catalytic residue

273 The catalytic activity of an artificial phosphodiesterase that combines a ligated metal ion (Cu(

274 us limits type I IFN by expressing a surface phosphodiesterase that degrades extracellular bacterial

275 mutant phenotypes were gdpP, which encodes a phosphodiesterase that degrades the second messenger cyc

276 VieA is a cyclic diguanylate phosphodiesterase that modulates biofilm development and

277 ative C16orf57/USB1 gene encodes a conserved phosphodiesterase that regulates the stability of splice

278 Tdp1 and Tdp2 are two tyrosyl-DNA phosphodiesterases that can repair damaged DNA resulting

279 lon genes glpQ and phoD as encoding secreted phosphodiesterases that function in WTA metabolism durin

280 d DON production, and Pde2 is the major cAMP phosphodiesterase to negatively regulate DON biosynthesi

281 o a broad family of diguanylate cyclases and phosphodiesterases to highlight their specific role in m

282 In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific a

283 Phosphodiesterase type 4 (PDE4) is a family of enzymes t

284 Laboratory evidence suggests that reduced phosphodiesterase type 5 (PDE5) expression increases the

285 get for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a

286 gh inhibition of the cGMP-hydrolyzing enzyme phosphodiesterase type 5 (PDE5) might exert renoprotecti

287 clic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role

288 eroxide dismutase (60.7 +/- 6.3%), increased phosphodiesterase type 5 expression (167 +/- 13.7%) and

289 evented by elevation of cGMP levels with the phosphodiesterase type 5 inhibitor sildenafil.

290 Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the acti

291 at vessels, these effects were reversed by a phosphodiesterase type 5 inhibitor.

292 d in rat mesenteric vessels with and without phosphodiesterase type 5 inhibitor.

293 In men, medication such as phosphodiesterase type 5 inhibitors may be beneficial, a

294 st-LT, and endothelin receptor antagonist or phosphodiesterase type 5 inhibitors were continued in 15

295 GMP synthesis or blocking its degradation by phosphodiesterase type 5A (PDE5A) protects against cardi

296 he cytosolic chaperone delta-subunit of cGMP phosphodiesterase type 6 (PDE6delta).

297 Treatment with phosphodiesterase type-5 inhibitors and oral or inhaled

298 1R7, cold-shock domain protein A (CSDA), and phosphodiesterase type-5A (PDE5A) in PAF patients, with

299 esents a broadly conserved class of c-di-AMP phosphodiesterase with possibly other physiological func

300 late cyclase with forskolin or inhibition of phosphodiesterase with rolipram produced similar effects